BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/22/2022 7:03:59 AM | Browse: 315 | Download: 904
 |
Received |
|
2022-02-28 07:53 |
|
Peer-Review Started |
|
2022-02-28 07:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-05-11 09:55 |
|
Revised |
|
2022-05-19 08:53 |
|
Second Decision |
|
2022-06-17 03:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-06-17 23:20 |
|
Articles in Press |
|
2022-06-17 23:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-06-13 02:07 |
|
Typeset the Manuscript |
|
2022-07-11 00:19 |
|
Publish the Manuscript Online |
|
2022-07-22 07:03 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Prognostic role of multiple abnormal genes in non-small-cell lung cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lu-Da Yan, Liu Yang, Na Li, Meng Wang, Yan-Hua Zhang, Wen Zhou, Zhi-Qiong Yu, Xiao-Chun Peng and Jun Cai |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Hubei Province |
2017CFB786 |
| Hubei Province Health and Family Planning Scientific Research Project |
WJ2016Y10 |
| Jingzhou Science and Technology Bureau Project |
2017-93 |
| College Students Innovative Entrepreneurial Training Program in Yangtze University |
2019376 |
|
| Corresponding Author |
Jun Cai, MD, PhD, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Yangtze University, No. 1 Nanhuan Road, Jingzhou 434023, Hubei Province, China. 529369023@qq.com |
| Key Words |
Non-small-cell lung cancer; Gene mutation; Tyrosine kinase inhibitor; Overexpression; Next-generation sequencing; Epidermal growth factor receptor; KRAS |
| Core Tip |
Non-small-cell lung cancer (NSCLC) has the highest morbidity and mortality rates among all malignant tumors. To explore the impact of simultaneous abnormalities of multiple genes on the prognosis and survival of patients. We used R packages to analyze gene expression data and clinical data downloaded from The Cancer Genome Atlas database. We also collected samples from 85 NSCLC patients from the First People's Hospital of Jingzhou City and retrospectively followed the patients for multivariate Cox regression analysis and survival analysis. Co-occurring mutation or overexpression of different genes has different effects on the overall survival and prognosis of patients. Combined with TKI treatment, the co-occurring mutation of some genes may have a synergistic effect on the survival and prognosis of NSCLC patients. |
| Publish Date |
2022-07-22 07:03 |
| Citation |
Yan LD, Yang L, Li N, Wang M, Zhang YH, Zhou W, Yu ZQ, Peng XC, Cai J. Prognostic role of the abnormal multiple genes in non-small-cell lung cancer. World J Clin Cases 2022; 10(22): 7772-7784 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i22/7772.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i22.7772 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
